Lantheus

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Lantheus and other ETFs, options, and stocks.

About LNTH

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease.

CEO

Mary Anne Heino

CEOMary Anne Heino

Employees

1,193

Employees1,193

Headquarters

Bedford, Massachusetts

HeadquartersBedford, Massachusetts

Founded

1956

Founded1956

Employees

1,193

Employees1,193

LNTH Key Statistics

Market cap

5.20B

Market cap5.20B

Price-Earnings ratio

23.57

Price-Earnings ratio23.57

Dividend yield

—

Dividend yield—

Average volume

1.38M

Average volume1.38M

High today

$82.00

High today$82.00

Low today

$79.66

Low today$79.66

Open price

$81.53

Open price$81.53

Volume

981.64K

Volume981.64K

52 Week high

$108.91

52 Week high$108.91

52 Week low

$47.25

52 Week low$47.25

Stock Snapshot

The current Lantheus(LNTH) stock price is $80.42, with a market capitalization of 5.2B. The stock trades at a price-to-earnings (P/E) ratio of 23.57.

During the trading session on 2026-03-13, Lantheus(LNTH) shares reached a daily high of $82.00 and a low of $79.66. At a current price of $80.42, the stock is +1.0% higher than the low and still -1.9% under the high.

Trading activity shows a volume of 981.64K, compared to an average daily volume of 1.38M.

Over the past 52 weeks, Lantheus(LNTH) stock has traded between a high of $108.91 and a low of $47.25.

LNTH News

Simply Wall St 3h

Lantheus Holdings Is Up 5.4% After New PYLARIFY TruVu And LUTATHERA Approvals - Has The Bull Case Changed?

Lantheus Holdings recently received FDA approval for PYLARIFY TruVu, an enhanced formulation of its PSMA PET imaging agent for prostate cancer, and tentative FD...

Simply Wall St 3d

A Look At Lantheus Holdings Valuation After FDA Approval Of PYLARIFY TruVu

Lantheus Holdings (LNTH) is back in focus after U.S. regulators cleared PYLARIFY TruVu, a new formulation of its PSMA PET imaging agent for prostate cancer that...

TipRanks 6d

Lantheus announces FDA approval of Pylarify TruVu injection

Lantheus (LNTH) announced that the FDA has approved Pylarify TruVu injection, a new formulation of its F 18 prostate-specific membrane antigen imaging agent. Py...

Analyst ratings

85%

of 13 ratings

Buy

84.6%

Hold

15.4%

Sell

People also own

Based on the portfolios of people who own LNTH. This list is generated using Robinhood data, and it’s not a recommendation.

Trade Desk

AMD

Novo Nordisk

Taiwan Semiconductor Manu…

CrowdStrike Holdings

PayPal

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.